Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls
NCT ID: NCT01263847
Last Updated: 2018-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
31 participants
INTERVENTIONAL
2009-06-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults
NCT06068894
Effect of Galacto-oligosaccharides (GOS) on Faecal Gut Microbiota in Adult Women
NCT05762965
The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals
NCT06915129
Effects of Low Lactose Milk Containing GOS on Digestive Response in Healthy Chinese Adults
NCT06598124
Galacto-oligosaccharides and Intestinal Activity
NCT04104360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No Galactooligosaccharide
0 g galactooligosaccharide added to calcium-containing yogurt beverage
Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
5 g Galactooligosaccharide
5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
10 g Galactooligosaccharide
10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Calcium intake of 900-1300 mg/d
Exclusion Criteria
* Any disorder of calcium or bone homeostasis
* BMI\>90th percentile for age
* Smoking, illegal drug consumption
* Any gastrointestinal disease (crohn's disease, celiac disease, inflammatory bowel disease)
* Any disease affecting kidney function
* Broken bone within last 6 months
* Dislike of yogurt or yogurt drinks
* Regular use of foods containing probiotics or prebiotics
10 Years
12 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Friesland Foods
UNKNOWN
Purdue University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Berdine Martin
Research Scientist, Nutrition Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Connie M Weaver, PhD
Role: PRINCIPAL_INVESTIGATOR
Purdue University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Purdue University
West Lafayette, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Friesland
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.